Moberg Pharma
18.77
SEK
+2.96 %
MOB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
6 following
+2.96%
+62.51%
-42.1%
-29.17%
+23.49%
+127.52%
-50.99%
-90.73%
-68.58%
www.mobergpharma.se
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MOB
Daily low / high price
18.29 / 19.59
SEK
Market cap
898.7M SEK
Turnover
5.3M SEK
Volume
277K
Latest videos
Financial calendar
Annual report
2025-02-11
Interim report
2025-05-13
General meeting
2025-05-22
Interim report
2025-08-12
Interim report
2025-11-11
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| IBKR Financial Services AG, W8IMY | 9.9 % | 9.9 % |
| Östersjöstiftelsen | 9.0 % | 9.0 % |
| Avanza Pension | 4.6 % | 4.6 % |
| Kjelsmark Holding ApS | 3.3 % | 3.3 % |
| Moberg Pharma AB | 2.5 % | 2.5 % |
| CBNY-National Financial Services Ll | 2.4 % | 2.4 % |
| Morgan Stanley & Co Intl Plc, W-8imy Qdd | 2.1 % | 2.1 % |
| UBS AG London Branch, W8imy | 2.0 % | 2.0 % |
| Nordnet Pensionsförsäkring | 1.9 % | 1.9 % |
| SEB AB, Luxembourg Branch, W8imy | 1.9 % | 1.9 % |
ShowingAll content types
Moberg Pharmas delårsrapport januari - september 2024
Moberg Pharma's Interim report January - September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools